{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-012446","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.550834+00:00","generated_at":"2026-06-19T09:40:14.598073+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jasper Therapeutics reports positive briquilimab data: 3 SCD patients achieve 100% donor chimerism","bullets":["First two sickle cell disease patients achieved 100% donor myeloid chimerism at Day 100; third at Day 30.","All three patients increased hemoglobin at last follow-up (to 11.4–14 g/dL from baseline 8–10 g/dL).","No graft-versus-host disease or briquilimab-related severe adverse events observed.","Data presented in plenary session at 2023 Tandem Meetings (ASTCT/CIBMTR) on novel antibody-based conditioning.","Study is Phase 1/2 (NCT05357482) evaluating briquilimab as conditioning for bone marrow transplant in SCD and beta thalassemia."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-012446","json":"https://secwatch.observer/filing/0001213900-23-012446.json","markdown":"https://secwatch.observer/filing/0001213900-23-012446.md","text":"https://secwatch.observer/filing/0001213900-23-012446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023012446/0001213900-23-012446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023012446/ea173843-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T09:40:14.598073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}